High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease

Autores

  • Fernanda Machado Balzan Hospital de Clínicas de Porto Alegre
  • Eder Chaves Pacheco Laboratório de Pneumologia LIM-09, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,
  • Fernando Nataniel Vieira Hospital de Clínicas de Porto Alegre
  • Joares Luiz moretti Jr Hospital de Clínicas de Porto Alegre
  • Bruna Maciel Catarino
  • Augusto Savi Hospital de Clínicas de Porto Alegre

Palavras-chave:

respiratory failure, interstitial lung disease, high flow nasal cannula

Resumo

Introduction. High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after failure of conventional therapy (SatO2< 90% offering 100% FiO2 by non-rebreathing mask or noninvasive ventilation). Results. Ten patients had success with HFNC (not requiring orotracheal intubation) during emergency department admission. HFNC significantly improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/min to 23 ± 3 breaths/min; PaO2 increased from 48.7 (38 - 59)mmHg to 81.1 (76 - 90) mmHg; PaO2/FiO2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO2 increased from 85 (66 - 92)% to 96 ± (95 - 97)%. HFNC could be an effective alternative in the treatment of acute respiratory failure from acute exacerbations of fibrotic ILD.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2020-07-15

Como Citar

1.
Balzan FM, Pacheco EC, Vieira FN, moretti Jr JL, Catarino BM, Savi A. High flow nasal cannula oxygen therapy in acute respiratory failure from acute exacerbation of fibrotic interstitial lung disease. Clin Biomed Res [Internet]. 15º de julho de 2020 [citado 29º de março de 2024];40(1). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/98187